Treatment of acne with red light photodynamic therapy

Not Applicable

Completed

Conditions: Mild to moderate acne vulgaris
Skin and Connective Tissue Diseases
Acne vulgaris

Registration Number: ISRCTN66066651

Lead Sponsor: Cantabria Labs Difa Cooper

Brief Summary: 2019 results in https://pubmed.ncbi.nlm.nih.gov/29790262/ (added 23/11/2020)

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 35

Inclusion Criteria

Mild to moderate acne vulgaris

Exclusion Criteria

1. Severe acne
2. Skin phototype I
3. Positive history of skin tumor
4. Photodermatosis

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

A study looking at how effective and safe a very low dose of dexamethasone is in helping ventilator-dependent preterm babies who are at high risk of bronchopulmonary dysplasia (a serious lung condition that affects infants) get off the ventilator more quickly and effectively

CompletedPhase 2

niversity of Liverpool

Updated 1/13/2020

A study to investigate the effect of a sensitivity toothpaste in providing relief from tooth sensitivity

CompletedNot Applicable

GlaxoSmithKline Consumer Healthcare

Updated 4/27/2020

ens replacement planning in patients with cataracts and corneal astigmatism using the iTrace program

CompletedNot Applicable

Shanxi Eye Hospital

Updated 2/1/2021

Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial

ovo Nordisk A/S

Updated 8/28/2012

Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial - ND

OVO NORDISK

Updated 8/28/2012

Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial

ovo Nordisk A/S

Updated 8/28/2012

Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exercise A 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial

Phase 1

ovo Nordisk A/S

Updated 11/25/2019

Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial

ovo Nordisk A/S

Updated 8/28/2012

Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial

Phase 1

ovo Nordisk A/S

Updated 12/21/2021

Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metformin or controlled with diet and exerciseA 12 week multi-centre, multi national, double-blind, placebo-controlled, randomised, nine armed parallel group, dose finding trial

ovo Nordisk A/S

Updated 8/28/2012

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Home Terms & Conditions Privacy Policy